ClinicalTrials.gg
CompletedNCT00522041Updated Nov 3, 2016Results posted

A Study to Determine the Effect of Nitroglycerin Ointment 0.4% (Cellegesic) on the Pain Associated With Chronic Anal Fissures

A Phase 3 interventional study of Cellegesic and Placebo in Fissure in Ano and Pain, sponsored by Forest Laboratories. Completed. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2016-11-03.

Sponsored by Forest Laboratories (part of AbbVie) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
248
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Study summary

Anal fissure is a solitary ulcer in the squamous epithelium of the anus causing intense anal pain especially during defecation and for 1 or 2 hours afterwards. There are no approved drugs in the United States (US) for this condition and surgery is often the treatment choice. Strakan is conducting this confirmatory study so the product can be submitted for regulatory approval in the US. Strakan currently markets this product throughout Europe.

The objective of this study is to determine the effect of nitroglycerin ointment 0.4% (Cellegesic) versus placebo on average pain intensity over every 24 hour period for up to 21 days of treatment in 250 patients.

02

Conditions studied

  • Fissure in Ano
  • Pain

Keywords

  • Pain associated with chronic anal fissure
03

In context

Fissure in Ano

84 studies on the registry are indexed under Fissure in Ano; 16 are open to participants now.

This study's enrollment of 248 is above the median of 99 across 65 interventional studies indexed under Fissure in Ano.

Browse Fissure in Ano studies →

Lead sponsor

Forest Laboratories is the lead sponsor of 168 studies on the registry; none are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 6 (100%) have results posted.

First submitted before Forest Laboratories became part of AbbVie.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Consenting patients of either sex.
  • Between 18 and 75 years of age.
  • With a single, chronic, posterior midline anal fissure.
  • Defined as having anal pain for the 6 weeks prior to Screening.

Exclusion criteria

Exclusion Criteria:

  • More than one anal fissure.
  • A fistula-in-ano or anal abscess.
  • Inflammatory bowel disease.
  • Fibrotic anal stenosis.
  • Anal fissure secondary to an underlying condition.
  • Any anal surgery.
  • Concomitant medication that may interfere with study evaluation.
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
248 participants (actual)

Study arms

  • Experimental
    Cellegesic (nitroglycerin 0.4%)

    Participants applied Cellegesic 375 mg ointment containing approximately 1.5 mg of nitroglycerin anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.

    Drug: Cellegesic

  • Placebo comparator
    Placebo 375 mg

    Participants applied placebo 375 mg ointment anally twice daily for 21 days. In addition, participants took acetaminophen 650 mg orally twice daily for 21 days.

    Drug: Placebo

Interventions

  • Cellegesic was supplied as an ointment containing 0.4% w/w nitroglycerin.

    Also known as: 0.4% nitroglycerin ointment, Rectogesic

  • DrugPlacebo

    Placebo was supplied as an ointment identical to Cellegesic ointment except that it contained no nitroglycerin.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Pain Intensity at Days 14-18

    Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated and used to determine the change from Baseline. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A negative change score indicated improvement.

    Time frame: Baseline to Day 18

Secondary outcomes

  1. Time to an Improvement in Pain Intensity

    Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale (VAS) at Baseline and on each of the 21 treatment days of the study. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. Improvement was defined as either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in rated pain intensity.

    Time frame: Baseline to Day 21

  2. Percentage of Responders

    Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A responder was defined as a participant with either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in the 24 hour average pain intensity averaged over Days 14 to 18.

    Time frame: Baseline to Day 18

07

Results

Posted Nov 3, 2016

Participant flow

Participant flow — Overall Study
MilestoneCellegesic (Nitroglycerin 0.4%)Placebo
Started123125
Received treatment123124
Completed106113
Not completed1712
Withdrew: Adverse event93
Withdrew: Protocol violation20
Withdrew: Lost to follow-up14
Withdrew: Voluntary withdrawal54
Withdrew: Did not receive treatment01

Outcome measures

PrimaryChange From Baseline in Pain Intensity at Days 14-18

Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated and used to determine the change from Baseline. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A negative change score indicated improvement.

Time frame:
Baseline to Day 18
Reported as:
Mean · Units on a scale
Change From Baseline in Pain Intensity at Days 14-18
Units on a scaleCellegesic (Nitroglycerin 0.4%)Placebo
Change From Baseline in Pain Intensity at Days 14-18-40.4 ± 3.12-34.9 ± 3.04
SecondaryTime to an Improvement in Pain Intensity

Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale (VAS) at Baseline and on each of the 21 treatment days of the study. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. Improvement was defined as either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in rated pain intensity.

Time frame:
Baseline to Day 21
Reported as:
Mean · Days
Time to an Improvement in Pain Intensity
DaysCellegisic (Nitroglycerin 0.4%)Placebo
≥ 50% decrease10.7 ± 0.613.2 ± 0.7
≥ 10 mm decrease6.1 ± 0.57.2 ± 0.6
SecondaryPercentage of Responders

Participants rated the pain associated with their chronic anal fissure over the preceding 24 hours on a 100 mm visual analog scale at Baseline and on Days 14 through 18. The average pain rating on Days 14 through 18 was calculated. The left-end of the visual analog scale was labelled "least possible pain" and the right-end of the visual analog scale was labelled "worst possible pain". The pain rating ranged from 0 to 100, with a higher score indicating more pain. A responder was defined as a participant with either a ≥ 50% decrease or a ≥ 10 mm decrease from Baseline in the 24 hour average pain intensity averaged over Days 14 to 18.

Time frame:
Baseline to Day 18
Reported as:
Number · Percentage of responders
Percentage of Responders
Percentage of respondersCellegisic (Nitroglycerin 0.4%)Placebo
≥ 50% decrease72.464.5
≥ 10 mm decrease88.685.5

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cellegesic (Nitroglycerin 0.4%)—2/123 (1.6%)96/123 (78%)
Placebo—1/124 (0.8%)67/124 (54%)
Most frequent serious events
Most frequent serious events
EventCellegesic (Nitroglycerin 0.4%)Placebo
OsteomyelitisInfections and infestations1/1230/124
Anal sphincterotomySurgical and medical procedures1/1230/124
Iron deficiency anaemiaBlood and lymphatic system disorders0/1231/124
Most frequent other events
Most frequent other events
EventCellegesic (Nitroglycerin 0.4%)Placebo
HeadacheNervous system disorders86/12359/124
DizzinessNervous system disorders6/1232/124
NauseaGastrointestinal disorders2/1235/124
DiarrhoeaGastrointestinal disorders4/1234/124
SinusitisInfections and infestations3/1231/124

Baseline characteristics

Safety population: All participants who received at least 1 application of study medication.

Age, Categorical
Age, Categorical(Participants)Cellegesic (Nitroglycerin 0.4%)PlaceboTotal
<=18 years000
Between 18 and 65 years114117231
>=65 years9716
Age, Continuous
Age, Continuous(years)Cellegesic (Nitroglycerin 0.4%)PlaceboTotal
Mean46.5 ± 12.6143.4 ± 13.2245.0 ± 12.99
Sex: Female, Male
Sex: Female, Male(Participants)Cellegesic (Nitroglycerin 0.4%)PlaceboTotal
Female5858116
Male6566131
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Cellegesic (Nitroglycerin 0.4%)PlaceboTotal
Hispanic or Latino233154
Not Hispanic or Latino10093193
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Cellegesic (Nitroglycerin 0.4%)PlaceboTotal
American Indian or Alaska Native033
Asian022
Native Hawaiian or Other Pacific Islander011
Black or African American211637
White9996195
More than one race000
Unknown or Not Reported369
08

Study locations

No study locations are listed for this record.

09

References and documents

Publications

  • Berry SM, Barish CF, Bhandari R, Clark G, Collins GV, Howell J, Pappas JE, Riff DS, Safdi M, Yellowlees A. Nitroglycerin 0.4% ointment vs placebo in the treatment of pain resulting from chronic anal fissure: a randomized, double-blind, placebo-controlled study. BMC Gastroenterol. 2013 Jul 1;13:106. doi: 10.1186/1471-230X-13-106. PubMed 23815124 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2007, a primary completion of Jul 2008 and a completion of Jul 2008. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 8 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2007
First posted
Aug 29, 2007
Start
Aug 2007
Primary completionActual
Jul 2008
CompletionActual
Jul 2008
Results first posted
Nov 3, 2016
Last update
Nov 3, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00522041
Responsible party
Sponsor
First posted
Aug 29, 2007
Start date
Aug 2007
Primary completion
Jul 2008
Completion
Jul 2008
Results posted
Nov 3, 2016
Last update
Nov 3, 2016

Study contacts

Gemma Clark
study director · Strakan Pharmaceuticals, Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nitroglycerin

Start the discussion